Loading...
XNASRDHL
Market cap8mUSD
Dec 24, Last price  
6.35USD
1D
0.47%
1Q
-34.10%
Jan 2017
-99.94%
IPO
-99.95%
Name

Redhill Biopharma Ltd

Chart & Performance

D1W1MN
XNAS:RDHL chart
P/E
0.34
P/S
1.24
EPS
18.76
Div Yield, %
0.00%
Shrs. gr., 5y
62.55%
Rev. gr., 5y
-4.87%
Revenues
7m
-89.46%
023,00016,00012,0007,014,0003,000101,0004,007,0008,360,0006,291,00064,359,00085,757,00061,800,0006,513,173
Net income
24m
P
-2,544,000-15,503,000-10,326,000-10,628,000-10,711,000-21,090,000-29,370,000-45,544,000-38,820,000-43,634,000-89,017,000-114,311,000-59,245,00023,916,000
CFO
-36m
L+22.73%
-1,632,000-4,691,000-6,795,000-8,436,000-12,229,000-17,826,000-28,258,000-44,769,000-34,462,000-40,749,000-48,579,000-65,047,000-29,185,000-35,820,000

Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
URL
https://www.redhillbio.com/
IPO date
Feb 01, 2011
Employees
113
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
6,513
-89.46%
61,800
-27.94%
85,757
33.25%
Cost of revenue
37,953
104,644
166,892
Unusual Expense (Income)
NOPBT
(31,440)
(42,844)
(81,135)
NOPBT Margin
Operating Taxes
(12,424)
16,567
Tax Rate
NOPAT
(31,440)
(30,420)
(97,702)
Net income
23,916
-140.37%
(59,245)
-48.17%
(114,311)
28.41%
Dividends
Dividend yield
Proceeds from repurchase of equity
13,959
23,806
78,536
BB yield
-5.90%
-10.96%
-2.62%
Debt
Debt current
718
116,248
1,618
Long-term debt
1,628
13,918
90,386
Deferred revenue
Other long-term liabilities
1,281
3,373
4,649
Net debt
(4,160)
110,033
37,831
Cash flow
Cash from operating activities
(35,820)
(29,185)
(65,047)
CAPEX
(11)
(198)
(115)
Cash from investing activities
4
8,302
(8,140)
Cash from financing activities
21,439
11,453
73,462
FCF
(23,037)
(33,391)
(97,252)
Balance
Cash
6,359
19,983
38,004
Long term investments
147
150
16,169
Excess cash
6,180
17,043
49,885
Stockholders' equity
(386,296)
(431,025)
(366,371)
Invested Capital
390,819
508,689
467,707
ROIC
ROCE
EV
Common stock shares outstanding
6,478
1,548
1,163
Price
36.50
-73.98%
140.30
-94.56%
2,580.00
-68.07%
Market cap
236,449
8.85%
217,219
-92.76%
3,001,010
-59.22%
EV
232,289
327,252
3,038,840
EBITDA
(29,450)
(34,690)
(62,986)
EV/EBITDA
Interest
367
41,333
16,567
Interest/NOPBT